Nov 28, 2025 15:50
ABBV - ABBVIE INC.
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 230.7 6.59 (2.86%) | -0.21 (-0.09%) | 0.16 (0.07%) | -0.06 (-0.02%) | 0.3 (0.13%) | 6.75 (2.93%) | -0.07 (-0.03%) | 0.98 (0.43%) |
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- 0.52
- Diluted EPS:
- 0.52
- Basic P/E:
- 456.3365
- Diluted P/E:
- 456.3365
- RSI(14) 1m:
- 65.08
- VWAP:
- 237.45
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Nov 28, 2025 05:28
Nov 24, 2025 12:25
Nov 19, 2025 17:24
Nov 19, 2025 14:37
Nov 17, 2025 12:17
Nov 17, 2025 10:25
Nov 15, 2025 12:25
Nov 13, 2025 09:08
Nov 11, 2025 22:05